SeekingAlphaSeptember 22, 2026 at 10:50 AM NYLast Month

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4

CADLCandel Therapeutics Inc

Candel Therapeutics is upgraded to Strong Buy after phase 3 prostate cancer win; 30% lower recurrence supports 2026 BLA. Click for this CADL update.

What This Story Means

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site: SeekingAlpha